07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

ARCHITECT Anti-CCP assay regulatory update

FDA granted 510(k) clearance for Axis-Shield's antibody cyclic-citrulinated peptide (anti-CCP) assay to aid in the diagnosis of rheumatoid arthritis for use on the Architect i1000SR and i2000SR immunoassay systems from Abbott Laboratories (NYSE:ABT, Abbott Park,...
08:00 , Mar 2, 2009 |  BC Week In Review  |  Clinical News

DIASTAT anti-CCP assay regulatory update

The U.K.'s NICE issued guidance on the management of rheumatoid arthritis in adults recommending measurement of anti-cyclic citrullinated peptide (CCP) antibodies in patients with suspected RA who are negative for rheumatoid factor and in whom...
07:00 , Apr 2, 2007 |  BC Week In Review  |  Clinical News

Anti-CCP assay regulatory update

FDA granted 510(k) clearance for ASD's anti-CCP assay for the early detection of rheumatoid arthritis (RA) when used in conjunction with the AxSYM automated immunoassay system from Abbott Laboratories (ABT, Abbott Park, Ill.). The test...
07:00 , Jul 14, 2003 |  BC Week In Review  |  Company News

Axis-Shield, Euro-Diagnostica Group deal

ASD sold its autoimmune diagnostics business to Euro-Diagnostica for £2.17 million ($3.6 million). The deal covers 24 ELISA kits and immunofluorescence slide tests. Initially, ASD will contract manufacture the products. Under a separate license agreement,...